ZYME vs. AKRO, MOR, SWTX, PTGX, CPRX, MRUS, ALVO, APLS, SRRK, and CRNX
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Zymeworks vs.
Zymeworks (NYSE:ZYME) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
In the previous week, Akero Therapeutics had 3 more articles in the media than Zymeworks. MarketBeat recorded 14 mentions for Akero Therapeutics and 11 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.21 beat Akero Therapeutics' score of 1.08 indicating that Zymeworks is being referred to more favorably in the media.
Akero Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Akero Therapeutics' return on equity.
Zymeworks has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Zymeworks has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
Zymeworks currently has a consensus target price of $21.00, suggesting a potential upside of 84.94%. Akero Therapeutics has a consensus target price of $76.29, suggesting a potential upside of 101.04%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Zymeworks.
92.9% of Zymeworks shares are held by institutional investors. 1.9% of Zymeworks shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Zymeworks received 177 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 67.74% of users gave Zymeworks an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote.
Summary
Zymeworks beats Akero Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
This page (NYSE:ZYME) was last updated on 4/15/2025 by MarketBeat.com Staff
Buy ZYME Stock Free ZYME Stock Alerts